The official renaming of polycystic ovary syndrome to polycystic ovary metabolic syndrome (PMOS) carries important implications for clinical practice and patient care. The new terminology reflects three critical changes: first, it broadens the diagnostic framework to encompass metabolic dysfunction—insulin resistance, cardiovascular risk factors, and endocrine disruption—beyond reproductive symptoms. Second, the name change acknowledges that not all patients develop characteristic ovarian cysts, reducing diagnostic barriers that previously contributed to missed cases.
Third, and perhaps most significantly, PMOS encourages multidisciplinary care coordination. Clinicians across endocrinology, cardiology, gynecology, and internal medicine should recognize their roles in comprehensive PMOS management. This shift promotes early identification of the estimated 70% of cases currently going undiagnosed and enables timely metabolic intervention to prevent long-term complications including cardiovascular disease and metabolic syndrome.
Healthcare organizations and practitioners should update diagnostic protocols accordingly.
Read the full article on GMJ Newsroom.
Was this article helpful?
